Values as of: 2024-12-24
COMMON STOCK | Drug Manufacturers - General |
Last Closing
USD 14.73Change
+0.03 (+0.20)%Market Cap
USD 3.94BVolume
1.14MAnalyst Target
N/AVerdict
Verdict
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Atozet, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. It sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
Company Website : https://www.organon.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| LLY | Eli Lilly and Company |
-0.61 (-0.08%) |
USD 690.46B |
| NVO | Novo Nordisk A/S |
-1.34 (-1.51%) |
USD 363.61B |
| JNJ | Johnson & Johnson |
+0.58 (+0.40%) |
USD 347.83B |
| ABBV | AbbVie Inc |
+1.61 (+0.90%) |
USD 310.27B |
| PFE | Pfizer Inc |
+0.03 (+0.11%) |
USD 145.81B |
| BMY | Bristol-Myers Squibb Company |
+0.18 (+0.31%) |
USD 116.28B |
| GSK | GlaxoSmithKline PLC ADR |
-0.03 (-0.09%) |
N/A |
| MRK | Merck & Company Inc |
+0.08 (+0.08%) |
N/A |
| NVS | Novartis AG ADR |
-0.10 (-0.10%) |
N/A |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| DES | WisdomTree U.S. SmallCap .. | 0.00 % | 0.38 % |
+0.29 (+0.00%) |
USD 2.18B |
| PQLC | 0.00 % | 0.00 % |
N/A |
N/A | |
| SLYV | SPDR® S&P 600 Small Cap .. | 0.00 % | 0.15 % |
+0.81 (+0.00%) |
N/A |
| VIOV | Vanguard S&P Small-Cap 60.. | 0.00 % | 0.20 % |
+0.93 (+0.00%) |
N/A |
| XPH | SPDR® S&P Pharmaceutical.. | 0.00 % | 0.35 % |
N/A |
N/A |
| Market Performance vs. Industry/Classification (Drug Manufacturers - General) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 2.15% | 70% | C- | 46% | F | ||
| Dividend Return | 7.77% | 100% | F | 86% | B+ | ||
| Total Return | 9.92% | 70% | C- | 53% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 4.25% | 70% | C- | 52% | F | ||
| Dividend Return | 7.93% | 100% | F | 86% | B+ | ||
| Total Return | 12.17% | 70% | C- | 59% | D- | ||
| Trailing 5 Years | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -12.42% | 10% | F | 4% | F | ||
| Dividend Return | -9.78% | 10% | F | 5% | F | ||
| Total Return | 2.64% | 30% | F | 59% | D- | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 20.65% | 40% | F | 53% | F | ||
| Risk Adjusted Return | -47.36% | 10% | F | 5% | F | ||
| Market Capitalization | 3.94B | 14% | F | 75% | C | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
This stock has shown below median revenue growth in the previous 5 years compared to its sector
